iCAD (NASDAQ:ICAD) Downgraded by StockNews.com to Sell

iCAD (NASDAQ:ICAD) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Tuesday.

iCAD Stock Performance

ICAD traded down $0.01 during midday trading on Tuesday, hitting $2.32. The stock had a trading volume of 199,432 shares, compared to its average volume of 247,663. The company has a market cap of $61.57 million, a P/E ratio of -17.85 and a beta of 1.95. The business has a fifty day moving average of $2.63 and a 200 day moving average of $2.05. iCAD has a 1 year low of $1.18 and a 1 year high of $3.78.

Institutional Trading of iCAD

Several hedge funds and other institutional investors have recently bought and sold shares of ICAD. waypoint wealth counsel boosted its stake in iCAD by 44.0% in the fourth quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock worth $26,000 after buying an additional 4,400 shares in the last quarter. Summit Trail Advisors LLC purchased a new stake in iCAD in the fourth quarter worth approximately $214,000. Thompson Davis & CO. Inc. purchased a new stake in iCAD in the fourth quarter worth approximately $31,000. First Eagle Investment Management LLC boosted its stake in iCAD by 6.1% in the fourth quarter. First Eagle Investment Management LLC now owns 716,161 shares of the technology company’s stock worth $1,311,000 after buying an additional 41,000 shares in the last quarter. Finally, PKS Advisory Services LLC purchased a new stake in iCAD in the fourth quarter worth approximately $53,000. Hedge funds and other institutional investors own 24.61% of the company’s stock.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.